Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays.

After hormone therapy, men with PSMA+ mCRPC who received PLUVICTO saw:
More time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy | Their tumors shrink or disappear, 49% of the time vs 14% with a second hormone therapy |
How does targeted treatment work for PSMA+ mCRPC?
PLUVICTO is given in up to 6 doses every 6 weeks
Brochures and pamphlets can support you or your loved one
Interested in receiving information about PLUVICTO?
PLUVICTO® Pulse provides educational support and materials for those considering and starting on treatment.
mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.